daa ’ s in the treatment of hcv: the beginning of the end or the end of the beginning for hcv?
Post on 13-Feb-2016
66 Views
Preview:
DESCRIPTION
TRANSCRIPT
DAA’s in the treatment of HCV: The Beginning of the end or the end of the
beginning for HCV?
HCV-Related Cirrhosis Is Projected to Peak Over the Next 10 Years
Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis
DAAs as Components of New Treatment Paradigm for Hepatitis C
Eric the Sailor
The story continues
Interferon has a Dual Mechanism of Action: Viral Inhibition and Immune Modulation
The addition of RBV Significantly Accelerates Viral Decay
Pharmacokinetics of Once Daily Compared with Twice Daily Regimen of Ribavirin
Eric’s HCV Treatment course
Definitions of Response
DAAs - Key Characteristics
Protease Inhibitor DAAs in Clinical Trials
5 Non Nucleoside Polymerase Inhibitors
4 Nucleoside Analogue Polymerase Inhibitors
4 NS5A Inhibitors
3 Other Classes
Eric Update
Eric comes ashore
Rash Decisions
Progress on study
Eric Week 24 to 48 and 72
Newly Approved HCV Agents: Telaprevir and Boceprevir
Treatment Naïve HCV G1
Sprint 2 Boceprevir Naïve
Sprint 2 SVR and Relapse Rates
SPRINT-2 and RESPOND-2: HCV G1 Subtype as a Predictor of SVR in Patients with Poor IFN Response (BOC Arms Combined)
Patients With Poor Interferon Response and Fail Treatment Are More Likely to Have RAVs
Changes in HCV RNA over Time During Previous Phase I Studies (101/103)
C219: HCV RNA Values over Time (Week 8 Interim Analysis, TVR-exposed)
MK 5172 Second Generation PI
Advance: SVR and Relapse Rates
Previously Treated Patients HCV G1
Respond-2
Respond-2
REALIZE: Insulin resistance was not an independent determinant of SVR
REALIZE: Impact of anemia/RBV dose reduction on SVR
PILLAR Study:TMC 435SVR24 (ITT)
Silen C 1 Virologic response BI 1335
Atlas Efficacy: Achievement of HCV RNA <15 IU/mL
PSI-7977 ELECTRON: Study Design for HCV GT2/3
PSI-7977 ELECTRON100% concordance of SVR12 with SVR24
PSI-7977 ELECTRONWhat is the role of Ribavirin?
BI 201335 and BI 207127, with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12
interim results of the SOUND-C2 study
SVR-12
Background
BMS-790052 (NS5A inhibitor) + BMS-650032 (PI) ± PR in null responders: phase IIa study
Virologic Response before and after treatment
Dual therapy with BMS 790052 + BMS 650032 in HCV genotype 1B null responsders
The Holy Grail
top related